Ogen GmbH
Records under this name other than the patents Ogen GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 6 of 6 · Back to Ogen GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,758,581 | Humanized anti-CD4 antibody with immunosuppressive properties Lapsed on the fee record Ended Sep 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 12, 2025 | From the USPTO record |
| US 8,586,715 | Humanized anti-CD4 antibody with immunosuppressive properties Term ended Term ended Aug 9, 2024 · From the USPTO record | Term ended | Term ended Aug 9, 2024 | From the USPTO record |
| US 8,440,806 | Humanized anti-CD4 antibody with immunosuppressive properties Term ended Term ended Jul 8, 2024 · From the USPTO record | Term ended | Term ended Jul 8, 2024 | From the USPTO record |
| US 7,452,981 | Humanized anti-CD4 antibody with immunosuppressive properties Term ended Term ended Mar 19, 2024 · From the USPTO record | Term ended | Term ended Mar 19, 2024 | From the USPTO record |
| US 8,673,304 | Humanized anti-CD4 antibody with immunosuppressive properties Term ended Term ended Mar 19, 2024 · From the USPTO record | Term ended | Term ended Mar 19, 2024 | From the USPTO record |
| US 8,685,651 | Method for screening for an anti-CD4 antibody suitable for use in immunotherapy Lapsed on the fee record Ended Apr 1, 2022 · From the USPTO record | Lapsed on the fee record | Ended Apr 1, 2022 | From the USPTO record |